On June 16, Reuters was 17 seconds ahead when Curevac said its COVID vaccine was only 47% effective. When subsequent trial data released on June 30 confirmed this low efficacy, Reuters was minutes ahead of the competition with the news.
Curevac’s COVID vaccine
The news of the vaccine effectiveness on June 16 more than halved the value of Curevac shares. After the trial data release a few weeks later, the company’s shares sunk by another 10%.